• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

3 Over-Priced Stocks With Weak Fundamentals

When a glamour stock loses the support of the momentum crowd, things can get ugly fast.
By TIM MELVIN Jan 05, 2017 | 01:00 PM EST
Stocks quotes in this article: HCSG, WWE, UA

The past few years I have sat down in the first half of January and put together a list of stocks I felt like investors should avoid for the next year. I kept it pretty simple and just screened for stocks that trade at very high multiples yet have low F-scores. This gives me a bunch of companies that are very popular with investors and traders but do not necessarily have the fundamentals that justify the price. I then added a simple filter and reduced the list to those that have under-performed the S&P 500 over the past month and may be starting to fall out of favor. When a glamour stock loses the support of the momentum crowd, things can get real ugly real fast.

The results have been pretty good. By good I mean most of the stocks did indeed continue to under-perform the market for a period. Some of them got decimated as momentum investors dumped their shares and moved onto the next exciting stock. The track record is not perfect as a few kept going higher, but for the last three years investors would have done well by avoiding or selling stocks that are highly valued and beginning to fall out of favor.

Top of the list again this year is Under Armour (UA) . This stock was an overvalued pick last year as well, and it's had a weak 2016. Under Armour has made just about every list of potentially overvalued stocks I have run for the past year, and the stock has not done much for the past few years. Although it made a good run, the stock is now down close to 2014 levels so long-term shareholders have had a roller-coaster ride but are now just treading water. The stock is trading at 66x earnings and has an F-score of just 3. Fundamentals would have to show rapid improvement even to begin to justify the current valuation, and I would avoid the stock for now. There are signs that traders are falling out of love as the stock is down 15% in the past month.

World Wrestling Entertainment (WWE) is another stock that appears to be slipping fundamentally and losing the support of their investor base. Once they announced a convertible bond deal in mid-December the stock sold off sharply as investors are concerned about dilution. While the WWE Network is a very good idea and should provide strong cash flows, I am not sure how much it will grow. A certain percentage of the population likes wrestling enough to use the service, but I am not certain how you grow that percentage. The stock is trading at 57x earnings, and the F-score is just 4 so I do not see a compelling reason to own the stock. There has been some takeout chatter around the stock, but keep in mind that the UFC buyout was done at a 22 EBITDA multiple and WWE is already trading at a multiple of 20 so there's not a lot of upside even if they get the same premium pricing.

Analysts have high expectations for Healthcare Services Group (HCSG) over the next year and it is reflected in the share price. The shares trade for 42x trailing earnings and 32x hoped-for earnings, so it's hard to make a case for the stock based on valuation. The company has an attractive business as they supply laundry, maintenance and dietary services to nursing homes, retirement communities, rehabilitation centers and hospitals in the U.S. I have to say that I like the business and if I could buy it at a single-digit EV/EBIT ratio instead of the current 27 multiples this might well be a backup-the-truck stock. Unfortunately, Wall Street likes the business as much as I do and the shares are far from a bargain. The F-score is just 4 right now, so the fundamental outlook is not as strong as the analyst's community is expecting. Should they miss estimates a time or two perhaps the stock would come down into the zone where we could buy it a bargain price, but for now I would avoid this stock.

Avoiding stocks with high multiples and low F-scores that are lagging the market has worked out very well the past few years. I suspect it will be again this year.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Melvin had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Consumer Discretionary | Entertainment | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • 12:20 PM EDT PAUL PRICE

    A Blast From the Past Regarding Bitcoin

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login